Skip to content

Impact of Intermittent Hypoxia on Neutrophil Extracellular Traps

Impact of Intermittent Hypoxia on Neutrophil Extracellular Traps

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05485688
Enrollment
100
Registered
2022-08-03
Start date
2023-01-31
Completion date
2025-07-31
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OSA

Keywords

obstructive sleep apnea, intermittent hypoxia, neutrophil extracellular traps

Brief summary

This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] & 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate). The test will be repeated if OSA patients receive CPAP therapy (continous positive airway pressure therapy).

Detailed description

Obstructive sleep apnea (OSA) is a common disease, affecting around one billion people worldwide. This disorder is characterized by repetitive upper airway collapse during sleep, thereby leading to intermittent hypoxia (IH). The severity of OSA is gauged by AHI(apnea-hypopnea index), which can be determined by a sleep test, polysomnography. Literature revealed OSA confers a higher risk for incident pneumonia and sepsis-related adverse outcomes, suggestive of defective immunity in those patients. CPAP therapy (continous positive airway pressure therapy) is the mainstay treatment for OSA. This research is aimed to investigate the impact of IH on the ability of neutrophils to produce neutrophil extracellular traps (NETs). We will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] & 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce NETs under the effect of PMA (phorbol 12-myristate 13-acetate).

Interventions

OTHERsleep apnea

This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] & 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).

Sponsors

Ministry of Science and Technology, Taiwan
CollaboratorOTHER_GOV
Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults with clinical diagnosis of moderate or severe OSA (AHI \>=15/hour) * Must be willing to participate in this study and sign permit

Exclusion criteria

* Not willing to participate in this study * Ever treated with continous positive airway pressure (CPAP) or other therapy for OSA * Age \< 20 years * Have comorbid disease or condition, which could impact immunity (such as malignancy, chemotherapy, immune disease, diabetes etc)

Design outcomes

Primary

MeasureTime frameDescription
ability to produce neutrophil extracellular traps (NETs)0-90 dyas (if receive therapy)Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate). The test will be repeated if OSA patients receive CPAP therapy (continous positive airway pressure therapy).

Contacts

Primary ContactKun-Ta Chou, MD & Ph.D
ale1371@yahoo.com.tw+886922407055

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026